- Open Access
Intravenous magnesium in subarachnoid hemorrhage
Critical Care volume 15, Article number: 427 (2011)
We would like to offer some comments on the updated meta-analysis on intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage , which was conducted by Wong and colleagues and published in a recent issue of Critical Care.
First, the authors did not mention a (non-blinded) randomized placebo-controlled trial conducted by Akdemir and colleagues and published in 2009 . Although this study would probably not pass Wong and colleagues' method of scrutiny, we believe that it should be mentioned alongside two other studies the authors described but did not include in the data analysis.
Second, the study by Westermaier and colleagues  should not be included in the data analysis. These authors, in contrast to those of the other included studies in which magnesium was used as an add-on therapy, did not use nimodipine in any of the included patients. Wong and colleagues exclude the study by Schmid-Elsaesser and colleagues  because nimodipine was not used in the magnesium group but omit doing the same for the study by Westermaier and colleagues.
Third, Figure 3  shows that the number of control subjects in 'Veyna 2002' was 20. However, in that study, the outcome data in the control group were present for only 16 patients (4 of the 20 patients were withdrawn because study requirements were not met) . Accordingly, the risk ratios in Figure 3 should be adjusted.
Fourth, given Wong and colleagues' definition of delayed cerebral ischemia, we wonder why the studies of Veyna and colleagues , Muroi and colleagues , and their own study in 2006  were not included in Figure 1. In the study by Veyna and colleagues , the outcome measure 'clinical vasospasm' was defined as a 'new focal neurological deficit that could not be accounted for by other causes'. Although the time frame in which this was scored is not mentioned, this was during the patients' stay in the intensive care unit and therefore would be clinically relevant to include in Figure 1. The same applies to the outcome measures 'delayed ischemic neurological deficit' in the study by Muroi and colleagues  and 'symptomatic vasospasm' in their own study in 2006 .
George KC Wong and Wai S Poon
First, it is unfortunate that the article by Akdemir and colleagues  slipped through the established search methodology for the journals. Nevertheless, the authors' results on the lack of an effect of magnesium sulphate infusion on clinical outcome echoed the conclusion of our review.
Second, the study by Schmid-Elsaesser and colleagues  compared magnesium sulphate infusion with nimodipine, the latter of which has an established beneficial effect on aneurysmal subarachnoid hemorrhage. The study by Westermaier and colleagues  was trickier in mentioning how their cohort of patients employed nimodipine in the Discussion section but not in the Results section. Westermaier and colleagues mentioned that they did not seek an alternative route of administration for oral tablet forms of nimodipine for intubated patients but did not mention that they would omit the nimodipine oral tablets in good-grade patients. This actually is the policy in some neurosurgical centers. The nature of the comparison between magnesium sulphate infusion with placebo infusion is also different from that of Schmid-Elsaesser and colleagues . Again, the omission of the data of Westermaier and colleagues did not alter the conclusion of the review.
Third, Veyna and colleagues  exposed a problem in the earlier study report format, in which numbers of patients were not mentioned in each step. Withdrawal could mean just the study medications, and the patients were assessed for intention-to-treat analysis. If the four control patients had been excluded, the result would have been the same (Figure 1) [5, 6, 9].
Fourth, the new definition of delayed cerebral ischemia included the subsets of patients with asymptomatic cerebral infarction , which turned out to be an important prognostic factor and which earlier studies ignored. Lastly, we would like to emphasize that the detrimental effect of higher-achieved plasma magnesium concentrations further supported the results of the current meta-analysis .
Wong GK, Poon WS, Boet R, Chan MT, Gin T, Ng SC, Zee B: Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage: an updated systemic review and meta-analysis. Crit Care 2011, 15: R52. 10.1186/cc10017
Akdemir H, Kulaksizogly O, Tucer B, Menku A, Postalci L, Gunaldi O: Magnesium sulfate therapy for cerebral vasospasm after aneurismal subarachnoid hemorrhage. Neurosurg Q 2009, 19: 35-39. 10.1097/WNQ.0b013e31818d0ecf
Westermaier T, Stetter C, Vince GH, Pham M, Tejon JP, Eriskat J, Kunze E, Matthies C, Ernestus RI, Solymosi L, Roosen K: Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized placebo-controlled, clinical study. Crit Care Med 2010, 38: 1284-1290.
Schmid-Elsaesser R, Kunz M, Zausinger S, Prueckner S, Briegel J, Steiger HJ: Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study. Neurosurgery 2006, 58: 1054-1065. 10.1227/01.NEU.0000215868.40441.D9
Veyna RS, Seyfried D, Burke DG, Zimmerman C, Mlynarek M, Nichols V, Marrocco A, Thomas AJ, Mitsias PD: Magnesium sulphate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg 2002, 96: 510-514. 10.3171/jns.2002.96.3.0510
Muroi C, Terzic A, Fortunati M, Yonekawa Y, Keller E: Magnesium sulphate in the management of patients with aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, dose-adapted trial. Surg Neurol 2008, 69: 33-39. 10.1016/j.surneu.2007.07.015
Wong GK, Chan MT, Boet R, Poon WS, Gin T: Intravenous magnesium sulfate after aneurysmal subarachnoid hemorrhage: a prospective randomized pilot study. J Neurosurg Anesthesiol 2006, 18: 142-148. 10.1097/00008506-200604000-00009
Wong GK, Poon WS, Chan MT, Boet R, Gin T, Ng SC, Zee BC, IMASH Investigators: Intravenous magnesium sulphate after aneurismal subarachnoid hemorrhage: a multi-center phase III study. Stroke 2010, 41: 921-926. 10.1161/STROKEAHA.109.571125
van den Bergh WM, Algra A, van Kooten F, Dirven CM, van Gijn J, Vermeulen M, Rinkel GJ, MASH Study Group: Magnesium sulphate in aneurismal subarachnoid hemorrhage. Stroke 2005, 36: 1011-1015. 10.1161/01.STR.0000160801.96998.57
Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijicks EF, Muizelaar JP, Mendelow AD, Juvela S, Yonas H, Terbrugge KG, Macdonald RL, Diringer MN, roderick JP, Drier JP, Roos YB: Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observation studies: proposal of a multidisciplinary research group. Stroke 2010, 41: 2391-2395. 10.1161/STROKEAHA.110.589275
Wong GK, Poon WS, Chan MT, Boet R, Gin T, Ng SC, Zee BC: Plasma magnesium concentrations and clinical outcomes in aneurismal subarachnoid hemorrhage patients: post-hoc analysis of Intravenous Magnesium Sulphate for Aneurysmal Subarachnoid Hemorrhage (IMASH) Trial. Stroke 2010, 41: 1841-1844. 10.1161/STROKEAHA.110.585232
The authors declare that they have no competing interests.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Abdo, W.F., Hoedemaekers, C.W. & van der Hoeven, J.G. Intravenous magnesium in subarachnoid hemorrhage. Crit Care 15, 427 (2011). https://doi.org/10.1186/cc10221
- Cerebral Ischemia
- Cerebral Infarction
- Magnesium Sulphate
- Aneurysmal Subarachnoid Hemorrhage